European Journal of Clinical Pharmacology

, Volume 64, Issue 9, pp 877-882

First online:

CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin

  • Yuan GaoAffiliated withDepartment of Pharmacology, School of Medicine, Zhengzhou University
  • , Li-rong ZhangAffiliated withDepartment of Pharmacology, School of Medicine, Zhengzhou University Email author 
  • , Qiang FuAffiliated withDepartment of Pharmacology, School of Medicine, Zhengzhou University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Our aim was to observe the impact of CYP3A4*1G genetic polymorphism on lipid-lowering efficacy of statins.


We studied 217 unrelated hyperlipidemic patients who prospectively received atorvastatin and 199 patients who received simvastatin as a single-agent therapy (20 mg day-1 p.o.) for 4 weeks. Genotyping of CYP3A4*1G was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were determined before and after treatment by enzymatic assays.


The frequency of CYP3A4*1G in Chinese hyperlipidemic patients was 0.276. After atorvastatin treatment, the mean percentage reduction in serum TC was 16.8 ± 3.3% (*1/*1), 17.8 ± 3.8% (*1/*1G), and 20.9 ± 5.0% (*1G/*1G), respectively. The CYP3A4*1G polymorphism had a gene-dose-dependent effect on percentage reduction in serum TC (P < 0.01). Conversely, there was no significant association between lipid-lowering efficacy of simvastatin and CYP3A4*1G polymorphism.


Carrying CYP3A4*1G increase the lipid-lowering efficacy of atorvastatin and may have no significant effect on simvastatin treatment.


CYP3A4 Polymorphisms Simvastatin Atorvastatin Lipid-lowering efficacy